{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:10:51Z","timestamp":1793034651777,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502800"],"award-info":[{"award-number":["2022YFC2502800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["TM202115PT"],"award-info":[{"award-number":["TM202115PT"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.phrs.2024.107335","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T09:42:47Z","timestamp":1723542167000},"page":"107335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: A systematic review, meta-analysis, and trial sequential analysis"],"prefix":"10.1016","volume":"208","author":[{"given":"Guanran","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junran","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2024.107335_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","article-title":"Current understanding of the molecular and cellular pathology of diabetic retinopathy","volume":"17","author":"Antonetti","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10153","key":"10.1016\/j.phrs.2024.107335_bib2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet (Lond., Engl. )"},{"issue":"647","key":"10.1016\/j.phrs.2024.107335_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2177","article-title":"Targeting C3b\/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"9735","key":"10.1016\/j.phrs.2024.107335_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","article-title":"Diabetic retinopathy","volume":"376","author":"Cheung","year":"2010","journal-title":"Lancet (Lond., Engl. )"},{"issue":"3","key":"10.1016\/j.phrs.2024.107335_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.phrs.2024.107335_bib6","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.phrs.2024.107335_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.phrs.2024.107335_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.phrs.2024.107335_bib9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol."},{"issue":"11","key":"10.1016\/j.phrs.2024.107335_bib10","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41433-020-0895-z","article-title":"Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade","volume":"34","author":"Adamis","year":"2020","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.phrs.2024.107335_bib11","first-page":"220","article-title":"One-year results of using a treat-and-extend regimen without a loading phase with anti-VEGF agents in patients with treatment-naive diabetic macular edema","volume":"241","author":"Schwarzer","year":"2019","journal-title":"Ophthalmol. J. Int. D. 'Ophtalmol. Int. J. Ophthalmol. Z. fur Augenheilkd."},{"issue":"6","key":"10.1016\/j.phrs.2024.107335_bib12","first-page":"453","article-title":"Real-life data in the treatment of neovascular age-related macular degeneration: results from the imaculaweb registry evaluated in a single Italian Medical Retina Center","volume":"243","author":"Nicol\u00f2","year":"2020","journal-title":"Ophthalmol. J. Int. D. 'Ophtalmol. Int. J. Ophthalmol. Z. fur Augenheilkd."},{"issue":"27","key":"10.1016\/j.phrs.2024.107335_bib13","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.phrs.2024.107335_bib14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.phrs.2024.107335_bib15","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.oret.2017.03.003","article-title":"Phase I Trial of anti-vascular endothelial growth factor\/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration","volume":"1","author":"Chakravarthy","year":"2017","journal-title":"Ophthalmol. Retin."},{"issue":"10326","key":"10.1016\/j.phrs.2024.107335_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet (Lond., Engl. )"},{"issue":"10326","key":"10.1016\/j.phrs.2024.107335_bib17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet (Lond., Engl. )"},{"issue":"9","key":"10.1016\/j.phrs.2024.107335_bib18","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.phrs.2024.107335_bib19","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.2147\/OPTH.S381503","article-title":"Faricimab for treatment-resistant diabetic macular edema","volume":"16","author":"Rush","year":"2022","journal-title":"Clin. Ophthalmol. (Auckl., NZ)"},{"key":"10.1016\/j.phrs.2024.107335_bib20","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.2147\/OPTH.S395279","article-title":"Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration","volume":"16","author":"Rush","year":"2022","journal-title":"Clin. Ophthalmol. (Auckl., NZ)"},{"key":"10.1016\/j.phrs.2024.107335_bib21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.phrs.2024.107335_bib22","first-page":"485","article-title":"New insights in resistant diabetic macular edema","volume":"244","author":"Kuroiwa","year":"2021","journal-title":"Ophthalmol. J. Int. D. 'Ophtalmol. Int. J. Ophthalmol. Z. fur Augenheilkd."},{"key":"10.1016\/j.phrs.2024.107335_bib23","unstructured":"Wells G.A., Wells G., Shea B., et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014; 2014."},{"key":"10.1016\/j.phrs.2024.107335_bib24","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.phrs.2024.107335_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J. Evid. Based Health"},{"issue":"4","key":"10.1016\/j.phrs.2024.107335_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"7414","key":"10.1016\/j.phrs.2024.107335_bib27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.phrs.2024.107335_bib28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jclinepi.2007.10.007","article-title":"Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses","volume":"61","author":"Brok","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107335_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","article-title":"Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis","volume":"61","author":"Wetterslev","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"7109","key":"10.1016\/j.phrs.2024.107335_bib30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.phrs.2024.107335_bib31","first-page":"3","article-title":"Evaluation of the effects of VEGF\/ANG-2 neutralization on vascular, neuronal and inflammatory pathologies in a spontaneous choroidal neovascularization (CNV) mouse model","volume":"59","author":"Foxton","year":"2018","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"27","key":"10.1016\/j.phrs.2024.107335_bib32","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.phrs.2024.107335_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/APO.0000000000000276","article-title":"To treat or not to treat: management options for symptomatic vitreous floaters","volume":"9","author":"Broadhead","year":"2020","journal-title":"Asia-Pac. J. Ophthalmol. (Phila., Pa)"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824002809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824002809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T23:10:31Z","timestamp":1726787431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824002809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"alternative-id":["S1043661824002809"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107335","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: A systematic review, meta-analysis, and trial sequential analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107335"}}